Short Term Effects of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects

Short Term Effects of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00345202

Enrollment

Registered

2006-06-27

Start date

2004-09-30

Completion date

2005-02-28

Last updated

2008-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

HMG-COA reductase inhibition, GFR, RPF, FE, CL

Brief summary

We wanted to test the shortterm effects of HMG-CoA reductase inhibition (atorvastatin) on renal hemodynamics, renal tubular function and vasoactive hormones on healthy subjects.

Interventions

DRUGHMG-CoA reductase inhibition (atorvastatin)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

20 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Both men and women * Age: Between 20-50 * BMI\<30

Exclusion criteria

* Cl. signs or history of disease of heart, lungs, kidneys or endocrine organs. * Abnormal lab. tests( haemoglobin, pl. sodium, pl. potassium, pl.creatinine, pl.bilirubin, pl.ALAT, pl. cholesterol, blood glucose) * Albuminuria or glucosuria * Cancer * Art. hypertension * Alcohol abuse * Med. treatment, except oral contraceptives * Pregnancy or breast feeding * Blood donation less than 1 month before study

Design outcomes

Primary

Measure	Time frame
GFR	—
RPF	—
FEna	—
FELi	—
CLna	—
CLli	—

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026